Tickwind
TodayOpportunitiesMarketsAI Chat
EN
Log inSign up
Tickwind

Read every tick. See where the market's blowing.

  • X
  • TelegramChinese
  • Newsletter

Product

  • Markets
  • Theme Zones
  • All stocks
  • Compare
  • Hot stocks
  • Opportunities
  • News
  • Discussion
  • Watchlist
  • What's new

Account

  • Settings
  • Newsletter
  • For writers
  • MCP server
  • Contact
  • Log in
  • Sign up
MarketsTheme ZonesAll stocksCompareHot stocksOpportunitiesNewsDiscussionWatchlistWhat's newSettingsNewsletterFor writersMCP serverContactLog inSign up

© 2026 Tickwind. Not investment advice.

Made for the curious investor.

Home/DMAC/Return on equity

DiaMedica Therapeutics Inc. (DMAC) Return on equity

DiaMedica Therapeutics Inc. (DMAC) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.

-62.5%FY2019
19
Fiscal yearValueYoY
FY2019-62.5%—

ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).

Source: SEC XBRL filings · For reference only · Not investment advice

More DMAC financial trends

DMAC RevenueDMAC Net incomeDMAC Net marginDMAC Gross profitDMAC Gross marginDMAC Operating incomeDMAC Operating marginDMAC Operating cash flowDMAC Free cash flowDMAC Capital expendituresDMAC Stock buybacksDMAC Dividends paidDMAC Total assetsDMAC Total liabilitiesDMAC Shareholders’ equityDMAC overview →